Current Research in Metabolic Syndrome and Cardiometabolic Disorders
A special issue of Metabolites (ISSN 2218-1989). This special issue belongs to the section "Endocrinology and Clinical Metabolic Research".
Deadline for manuscript submissions: 31 January 2026 | Viewed by 26
Special Issue Editors
Interests: atrial fibrillation; metabolic syndrome; stroke; dyslipidemia; endothelial dysfunction; heart failure; chronic coronary syndromes
Interests: metabolomics; mass spectrometry; metabolites identification; biomarker discovery; stable isotope flux; cancer metabolism; infectious diseases
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cardiovascular disorders are considered to be a leading cause of a low quality of life (QOL), increased Disability-Adjusted Life Years (DALY), and rising mortality rates. The highly close link between cardiovascular disease and metabolic disorders has led to a rise in new research fields. Although metabolic syndrome is not a disease itself, its presence significantly increases the likelihood of comorbidities and ultimately increases the risk of cardiovascular major events, thereby leading to higher mortality rates. In recent years, the existence of the paradoxical effects related to obesity, total cholesterol, LDL cholesterol, and even for the metabolic syndrome have come to light.
This Special Issue aims to reveal new discoveries in the field of metabolic dysfunction and their impact on cardiovascular diseases. We invite papers focusing on evaluating the relationships between dyslipidemia, elevated uric acid levels, obesity, diabetes mellitus or pre-diabetes and cardiovascular diseases (heart failure, cardiac arrhythmias, chronic or acute coronary syndromes, arterial hypertension, but not limited). In addition to this, we also invite studies on other forms of metabolic dysfunctions, such as metabolic dysfunction-associated steatotic liver disease, FIB-4 score, or novel scores, alongside their association with heart disease. Studies focusing on the correlations between COVID-19, metabolic dysfunctions and cardiovascular disease are welcome as well. In the last few years, we experienced a therapeutic revolution, in which drugs designed for the treatment of diabetes mellitus showed a major impact on heart health, raising hopes in patients with heart failure. The effect of these drugs on the metabolic syndrome remains debatable and studies in this domain are of interest, as well as the epidemiological aspects of metabolic syndrome.
Submissions may be made online until 31 January 2026. All papers submitted will be pre-checked, and if suitable for publication, will undergo a peer-review process. If accepted, the paper will be published as soon as possible.
Dr. Ciprian Ilie Rosca
Dr. Yunping Qiu
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- metabolic syndrome
- obesity
- dyslipidemias
- hyperuricemia
- diabetes mellitus
- cardiovascular diseases
- heart failure
- arrythmias
- acute or chronic coronary syndromes
- SGLT2-inhibitors
- metabolic liver diseases
- COVID-19 infection
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
